Answers are grounded in this paper and cite their sources.
Evaluates the timing of thrombotic microangiopathy to kidney allograft survival, suggesting its critical role in outcomes.
Post-transplant thrombotic microangiopathy (TMA) is an uncommon but clinically significant histologic finding associated with severe endothelial injury and high rates of graft loss. Its pathophysiology involves complement activation, endothelial dysfunction, and immune-mediated vascular injury, frequently in the context of antibody-mediated rejection (ABMR). The coexistence of TMA and ABMR reflects advanced microvascular and immunologic damage. This study evaluates the time of presentation of TMA and associated factors to kidney allograft survival.
No takes yet. Share an insight, caveat, or question.
Jimenez et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: